36
Participants
Start Date
March 19, 2018
Primary Completion Date
May 26, 2020
Study Completion Date
December 3, 2021
Talimogene Laherparepvec
Virally based anti-cancer immunotherapy given by direct injection into tumors.
Atezolizumab
A monoclonal antibody given by intravenous injection.
Universite Catholique de Louvain Cliniques Universitaires Saint Luc, Brussels
Hopitaux Universitaires de Geneve, Geneva
Liverpool Hospital, Liverpool
Inselspital Bern, Bern
Monash Medical Centre, Clayton
Breast Cancer Research Centre - WA, Nedlands
Fiona Stanley Hospital, Murdoch
Universitair Ziekenhuis Gent, Ghent
Columbia University Medical Center, New York
Charite Universitätsmedizin Berlin, Charité Campus Virchow-Klinikum, Berlin
Hospital General Universitario Gregorio Marañon, Madrid
Hospital Universitario Ramon y Cajal, Madrid
Universitätsklinikum Bonn, Bonn
Universitätsklinik Tübingen, Tübingen
University of California Los Angeles, Los Angeles
Stony Brook University, Stony Brook
Hospital del Mar, Barcelona
Lead Sponsor
Roche-Genentech
INDUSTRY
Amgen
INDUSTRY